1. Home
  2. Age-Related Macular Degeneration (ARMD) Doctors Near Me
  3. Clinical Trials
  4. Lutein by Scleral Iontophoresis in Patients With Stage 3 Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Lutein by Scleral Iontophoresis in Patients With Stage 3 Age-Related Macular Degeneration

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The objective of the clinical investigation is to evaluate the performance, safety and degree of tolerability resulting from the use of the iontophoresis medical device in adult subjects diagnosed with AMD stage 3 (AREDS classification) in one or both eyes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 100
Healthy Volunteers: t
View:

• Subjects (male or female) aged ≥ 55 years; Subject able to provide Informed Consent, in compliance with good clinical practice and current legislation

• Subject with age-related macular degeneration (AMD) category 3 in one or both eyes classified according to the criteria reported by Age-Related Eye Disease Study (AREDS) based on clinical manifestations:

• Subject in good general health; Manifest spherical equivalent refraction between +4.0 diopters (D) and - 4.0 D; Best corrected visual acuity (BCVA) for glasses ≤ 0.1 LogMAR; Intraocular pressure (IOP) ≤ 20 mmHg; Subjects able to cooperate with the Investigator; Subjects able to meet the requirements of the entire clinical investigation; Subject who qualifies for treatment with Iontoretina according to the approved indication;

Locations
Other Locations
Italy
Federico II University
RECRUITING
Naples
Contact Information
Primary
Ciro Costagliola, Director Of Ophthalmology Unit
ciro.costagliola@unina.it
+390817462394
Time Frame
Start Date: 2024-11-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 80
Related Therapeutic Areas
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Leads: Federico II University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Intra Ocular Pressure Monitoring After Intravitreal Injection of Aflibercept 8mg/0.07mL

Intra Ocular Pressure Monitoring After Intravitreal Injection of Aflibercept 8mg/0.07mL

Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable

A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMD

A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMD

Enrollment Status: Recruiting
Publish Date: January 16, 2025
Intervention Type: Drug

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Neovascular Age-related Macular Degeneration (AMD) That Shows no Response to Existing Therapy

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Neovascular Age-related Macular Degeneration (AMD) That Shows no Response to Existing Therapy

Enrollment Status: Recruiting
Publish Date: June 05, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved